Literature DB >> 11114709

Clinico-biological features of 30 patients with acute promyelocytic leukemia and response to combination induction chemotherapy with all-trans retinoic acid and anthracycline.

L C Lim1, M Vellupillai, A A Ghafar.   

Abstract

30 adult patients with acute promyelocytic leukemia (APL) were seen at our institution overthe past 7 years. Their white cell count at presentation ranged from 400/microl to 54,900/microl. Cytogenetic studies were successful in 28 patients, of which 26(93%) were positive for t(15;17). Molecular analysis by reverse-transcription polymerase chain reaction demonstrated the PML-RARalpha fusion transcript in all 30 patients. The majority of patients had breakpoints at the 3' end with bcr1 products predominating. Complete remission rate of 92% was achieved using all-trans retinoic acid and anthracycline as induction chemotherapy in 26 patients. Of these, retinoic acid syndrome was observed in 4 cases, with 1 fatality. In conclusion, APL is a distinct entity with a highly specific molecular marker - t(15;17) translocation - that can be successfully induced into remission with all-trans retinoic acid and anthracycline in most patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11114709     DOI: 10.1007/bf02782195

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  17 in total

Review 1.  Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia.

Authors:  F Lo Coco; D Diverio; B Falini; A Biondi; C Nervi; P G Pelicci
Journal:  Blood       Date:  1999-07-01       Impact factor: 22.113

2.  Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction.

Authors:  A Biondi; A Rambaldi; P P Pandolfi; V Rossi; G Giudici; M Alcalay; F Lo Coco; D Diverio; E M Pogliani; E M Lanzi
Journal:  Blood       Date:  1992-07-15       Impact factor: 22.113

3.  Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms.

Authors:  M Fagioli; M Alcalay; P P Pandolfi; L Venturini; A Mencarelli; A Simeone; D Acampora; F Grignani; P G Pelicci
Journal:  Oncogene       Date:  1992-06       Impact factor: 9.867

4.  All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results.

Authors:  S Castaigne; C Chomienne; M T Daniel; P Ballerini; R Berger; P Fenaux; L Degos
Journal:  Blood       Date:  1990-11-01       Impact factor: 22.113

5.  Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine.

Authors:  E Estey; P F Thall; S Pierce; H Kantarjian; M Keating
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

6.  Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study.

Authors:  J L Slack; D C Arthur; D Lawrence; K Mrózek; R J Mayer; F R Davey; R Tantravahi; M J Pettenati; S Bigner; A J Carroll; K W Rao; C A Schiffer; C D Bloomfield
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

7.  The "retinoic acid syndrome" in acute promyelocytic leukemia.

Authors:  S R Frankel; A Eardley; G Lauwers; M Weiss; R P Warrell
Journal:  Ann Intern Med       Date:  1992-08-15       Impact factor: 25.391

8.  Cytogenetic studies in acute promyelocytic leukemia: a survey of secondary chromosomal abnormalities.

Authors:  R Berger; M Le Coniat; J Derré; D Vecchione; P Jonveaux
Journal:  Genes Chromosomes Cancer       Date:  1991-09       Impact factor: 5.006

9.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

10.  Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.

Authors:  S De Botton; H Dombret; M Sanz; J S Miguel; D Caillot; R Zittoun; M Gardembas; A Stamatoulas; E Condé; A Guerci; C Gardin; K Geiser; D C Makhoul; O Reman; J de la Serna; F Lefrere; C Chomienne; C Chastang; L Degos; P Fenaux
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

View more
  1 in total

1.  How do tumors make ends meet?

Authors:  C Lengauer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.